Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1978 1
1979 2
1981 1
1982 1
1990 1
1996 1
1998 2
1999 2
2000 2
2001 6
2002 4
2003 11
2004 8
2005 2
2006 2
2007 2
2008 1
2009 3
2010 2
2014 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
Dalton H, Stirling DI. Dalton H, et al. Among authors: stirling di. Philos Trans R Soc Lond B Biol Sci. 1982 Jun 11;297(1088):481-96. doi: 10.1098/rstb.1982.0056. Philos Trans R Soc Lond B Biol Sci. 1982. PMID: 6125958
Clinical pharmacokinetics of thalidomide.
Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL. Teo SK, et al. Among authors: stirling di. Clin Pharmacokinet. 2004;43(5):311-27. doi: 10.2165/00003088-200443050-00004. Clin Pharmacokinet. 2004. PMID: 15080764 Review.
Thalidomide in the treatment of leprosy.
Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Teo S, et al. Among authors: stirling di. Microbes Infect. 2002 Sep;4(11):1193-202. doi: 10.1016/s1286-4579(02)01645-3. Microbes Infect. 2002. PMID: 12361920 Review.
Methylotrophs: genetics and commercial applications.
Lidstrom ME, Stirling DI. Lidstrom ME, et al. Among authors: stirling di. Annu Rev Microbiol. 1990;44:27-58. doi: 10.1146/annurev.mi.44.100190.000331. Annu Rev Microbiol. 1990. PMID: 2123619 Review. No abstract available.
Thalidomide and its impact in dermatology.
Stirling DI. Stirling DI. Semin Cutan Med Surg. 1998 Dec;17(4):231-42. doi: 10.1016/s1085-5629(98)80019-9. Semin Cutan Med Surg. 1998. PMID: 9859910 Review.
Alpha-fluoro-substituted thalidomide analogues.
Man HW, Corral LG, Stirling DI, Muller GW. Man HW, et al. Among authors: stirling di. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3415-7. doi: 10.1016/s0960-894x(03)00778-9. Bioorg Med Chem Lett. 2003. PMID: 14505639
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
Zou J, Jones RJ, Wang H, Kuiatse I, Shirazi F, Manasanch EE, Lee HC, Sullivan R, Fung L, Richard N, Erdman P, Torres E, Hecht D, Lam I, McElwee B, Chourasia AH, Chan KWH, Mercurio F, Stirling DI, Orlowski RZ. Zou J, et al. Among authors: stirling di. J Mol Med (Berl). 2020 Aug;98(8):1161-1173. doi: 10.1007/s00109-020-01943-6. Epub 2020 Jul 6. J Mol Med (Berl). 2020. PMID: 32632752
Thalidomide analogs and PDE4 inhibition.
Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chen Y, Stirling DI. Muller GW, et al. Among authors: stirling di. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. doi: 10.1016/s0960-894x(98)00475-2. Bioorg Med Chem Lett. 1998. PMID: 9873600
55 results